| Literature DB >> 32385954 |
John G F Cleland1, Robyn A Clark2, Pierpaolo Pellicori1, Sally C Inglis3.
Abstract
Entities:
Mesh:
Year: 2020 PMID: 32385954 PMCID: PMC7273055 DOI: 10.1002/ejhf.1864
Source DB: PubMed Journal: Eur J Heart Fail ISSN: 1388-9842 Impact factor: 15.534
Actionable measurements and interventions required for care of patients with heart failure
|
|
ACEi, angiotensin‐converting enzyme inhibitor; AF, atrial fibrillation; ARB, angiotensin receptor blocker; ARNI, angiotensin receptor–neprilysin inhibitor; BNP, B‐type natriuretic peptide; BP, blood pressure; CRT, cardiac resynchronisation therapy; Echo, echocardiography; GFR, glomerular filtration rate; HR, heart rate; ICD, implantable cardioverter‐defibrillator; K+, serum potassium; MRA, mineralocorticoid receptor antagonist; OAC, oral anti‐coagulant; QRS, QRS width on the electrocardiogram; Revascularisation, coronary revascularisation; SGLT2i, sodium–glucose co‐transporter 2 inhibitor; SOB, shortness of breath; Valve, valve procedure– mitral or aortic.
✓= required for monitoring during follow‐up; I = mainly for deciding on initiation or investigation; R? = consider reducing or temporarily stopping.
Black = currently widely available technologies (e.g.: ECG/sphygmomanometer). Blue = technology with limited availability for use at home (e.g. bio‐impedance, blood tests). Echo is in purple, because although home monitoring is unlikely in the near future, it plays an essential role in identifying reduced left ventricular ejection fraction and valve disease and therefore in treatment selection.
#BNP is a useful marker of poorly controlled congestion/heart failure and the need for further investigation/treatment.
*Water retention leading to oedema (an increase in water in the tissues). Detection and treatment of subclinical oedema can prevent symptoms and improve prognosis.